Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.

Fuchs H, Kishimoto W, Gansser D, Tanswell P, Ishiguro N.

Drug Metab Dispos. 2014 Oct;42(10):1761-5. doi: 10.1124/dmd.114.058545. Epub 2014 Jul 22.

PMID:
25053619
2.

Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects.

Guth BD, Narjes H, Schubert HD, Tanswell P, Riedel A, Nehmiz G.

Br J Clin Pharmacol. 2004 Jul;58(1):40-51.

3.

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.

Kloft C, Graefe EU, Tanswell P, Scott AM, Hofheinz R, Amelsberg A, Karlsson MO.

Invest New Drugs. 2004 Jan;22(1):39-52.

PMID:
14707493
4.

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.

Clin Cancer Res. 2003 May;9(5):1639-47.

5.

Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.

Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G.

Onkologie. 2003 Feb;26(1):44-8.

PMID:
12624517
6.

Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.

Tanswell P, Modi N, Combs D, Danays T.

Clin Pharmacokinet. 2002;41(15):1229-45. Review.

PMID:
12452736
7.

Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.

Tanswell P, Garin-Chesa P, Rettig WJ, Welt S, Divgi CR, Casper ES, Finn RD, Larson SM, Old LJ, Scott AM.

Br J Clin Pharmacol. 2001 Feb;51(2):177-80.

8.

Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.

Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald E.

J Clin Pharmacol. 2000 May;40(5):508-15.

PMID:
10806604
9.

Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical models.

Godfrey KR, Tanswell P, Bates RA, Chappell MJ, Madden FN.

Biopharm Drug Dispos. 1998 Mar;19(2):131-40.

PMID:
9533114
10.

Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.

Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, Uhlich F, Hauck S, Jost S, Rafflenbeul W, Lichtlen PR, Dietz R.

J Am Coll Cardiol. 1997 Dec;30(7):1611-7.

11.

Pharmacokinetic-pharmacodynamic and metabolite modeling with TopFit.

Tanswell P, Heinzel G, Weisenberger H, Roth W.

Int J Clin Pharmacol Ther. 1995 Oct;33(10):550-4.

PMID:
8574505
12.

TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program.

Tanswell P, Koup J.

Int J Clin Pharmacol Ther Toxicol. 1993 Oct;31(10):514-20.

PMID:
8262691
13.

Influence of acute myocardial infarction and rt-PA therapy on circulating fibrinogen.

Seifried E, Oethinger M, Tanswell P, Hoegee-de Nobel E, Nieuwenhuizen W.

Thromb Haemost. 1993 Apr 1;69(4):321-7.

PMID:
8497843
14.

Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism.

Tebbe U, Seifried E, Carlsson J, Tanswell P.

Blood Coagul Fibrinolysis. 1992 Aug;3(4):475-80.

PMID:
1420824
15.

Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.

Tanswell P, Tebbe U, Neuhaus KL, Gläsle-Schwarz L, Wojcik J, Seifried E.

J Am Coll Cardiol. 1992 Apr;19(5):1071-5.

16.

Studies on the functionality of fibrinogen during rt-PA therapy: results of three different methods of fibrinogen determination.

Seifried E, Oethinger M, Tanswell P, Hoegee-de Nobel H, Nieuwenhuizen W.

Blood Coagul Fibrinolysis. 1992 Feb;3(1):81-7.

PMID:
1623123
17.

Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator.

Tanswell P, Seifried E, Stang E, Krause J.

Arzneimittelforschung. 1991 Dec;41(12):1310-9. Review.

PMID:
1815534
18.

Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients.

Reed BR, Chen AB, Tanswell P, Prince WS, Wert RM Jr, Glaesle-Schwarz L, Grossbard EB.

Thromb Haemost. 1990 Oct 22;64(2):276-80.

PMID:
2125377
19.

Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.

Tanswell P, Heinzel G, Greischel A, Krause J.

J Pharmacol Exp Ther. 1990 Oct;255(1):318-24.

PMID:
2120422
20.

Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.

Krause J, Seydel W, Heinzel G, Tanswell P.

Biochem J. 1990 May 1;267(3):647-52.

21.

Absolute bioavailability of pirenzepine in intensive care patients.

Tanswell P, Hofgärtner F, Bozler G, Giesler H, Allmendinger G, Schmid E.

Eur J Clin Pharmacol. 1990;38(3):265-8.

PMID:
2340846
22.

Current developments in thrombolytic therapy using novel plasminogen activators.

Seifried E, Tanswell P.

Arzneimittelforschung. 1989 Nov;39(11):1474-82. Review.

PMID:
2695093
23.

Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.

Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz KH, Herrmann KS.

Am J Cardiol. 1989 Sep 1;64(8):448-53.

PMID:
2505604
24.

Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects.

Tanswell P, Seifried E, Su PC, Feuerer W, Rijken DC.

Clin Pharmacol Ther. 1989 Aug;46(2):155-62.

PMID:
2503283
25.
26.

Properties of molecular variants of tissue-type plasminogen activator.

Krause J, Tanswell P.

Arzneimittelforschung. 1989 May;39(5):632-7. Review.

PMID:
2502992
27.

Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction.

Krakamp B, Tanswell P, Vogel H, Bozler G.

Eur J Clin Pharmacol. 1989;36(1):75-8.

PMID:
2917593
28.

Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.

Krakamp B, Tanswell P, Leidig P, Vogel H, Schmitz R, Bozler G.

Eur J Clin Pharmacol. 1989;36(1):71-3.

PMID:
2917592
29.

Pharmacokinetic and pharmacodynamic studies in man simulating acute and chronic treatment with oral pirenzepine.

Londong W, Londong V, Federle C, Tanswell P, Voderholzer U.

Eur J Clin Pharmacol. 1989;36(4):369-74.

PMID:
2737229
30.

Pharmacokinetics and biodisposition of recombinant human interferon-alpha 2C in rat and marmoset.

Greischel A, Tanswell P, Busch U, Schumacher K.

Arzneimittelforschung. 1988 Oct;38(10):1539-43.

PMID:
3196399
31.

Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers.

Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su CA, Kluft C.

Arzneimittelforschung. 1988 Mar;38(3):418-22.

PMID:
3132929
32.

[Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].

Seifried E, Böck F, Tanswell P, Rijken DC, Kluft C, Heimpel H.

Klin Wochenschr. 1988;66 Suppl 12:40-9. German.

PMID:
2450222
34.

Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction.

Seifried E, Tanswell P, Rijken DC, Kluft C, Hoegee E, Nieuwenhuizen W.

Lancet. 1987 Aug 8;2(8554):333-4. No abstract available.

PMID:
2886790
35.

A selective radioimmunoassay for the determination of pirenzepine in plasma and urine.

Homon CA, Esber HJ, Zavorskas P, Tanswell P, Farina PR.

Ther Drug Monit. 1987 Jun;9(2):236-42.

PMID:
3617165
36.
37.
38.

Immunological approaches to the structure of fibrinogen.

Tanswell P, Gollwitzer R, Stan-Lotter H, Timpl R.

Thromb Haemost. 1979 Jun 30;41(4):702-8. No abstract available.

PMID:
90395
39.

Structure of antigenic determinants in the amino-terminal region of bovine fibrinogen Aalpha chain.

Tanswell P, Reiter H, Timpl R.

Eur J Biochem. 1978 Aug 1;88(2):565-71. No abstract available.

40.

Immunochemistry of bovine fibrinogen--III. Localization of two antigenic determinants in fibrinopeptide B.

Tanswell P, Stan-Lotter H, Gollwitzer R, Timpl R.

Immunochemistry. 1977 Apr;14(4):277-81. No abstract available.

PMID:
68915
41.

Nuclear-magnetic-resonance study of the active-site structure of yeast phosphoglycerate kinase.

Tanswell P, Westhead EW, Williams RJ.

Eur J Biochem. 1976 Mar 16;63(1):249-62.

42.
43.

The internal structure of the chromaffin granule.

Daniels A, Korda A, Tanswell P, Williams A, Williams RJ.

Proc R Soc Lond B Biol Sci. 1974 Nov 5;187(1088):353-61. No abstract available.

PMID:
4154456
44.

Inhibition of yeast phosphoglycerate kinase by lanthanide-ATP complexes.

Tanswell P, Westhead EW, Williams RJ.

FEBS Lett. 1974 Nov 1;48(1):60-3. No abstract available.

Supplemental Content

Loading ...
Support Center